Download original image
Fig. 1. Experimental schedule and effect of Vinp on clinical changes in DNCB-induced AD. (A) Experimental schedule for DNCB-induced AD. (B) Representative images showing control and DNCB-induced AD mice treated with vehicle, Vinp at 1 mg/kg and 2 mg/kg, and Dex at 2 mg/kg. (C) Each region was separately assessed for four signs based on the EASI score: erythema, edema, excoriation, and lichenification. Each sign was assigned an intensity score from 0 to 3, with 0 indicating absence; 1: mild; 2: moderate; and 3: severe. Scores were evaluated through macroscopic observations. (D) TEWL levels in Balb/c dorsal skin were measured to assess the degree of moisture loss in the skin on the last day of the experiment (day 28). Data represent means ± SD (n = 5 or 6). Statistical analysis was performed using one-way ANOVA (Data were considered significant at ###p < 0.001 compared with the control group and *p < 0.1, **p < 0.01, ***p < 0.001 compared with the DNCB group). AD, atopic dermatitis; DNCB, 1-chloro-2,4-dinitrobenzene; Vinp, vinpocetine; Dex, dexamethasone; EASI, eczema area and severity index; TEWL, transepidermal water loss; PDE, phosphodiesterase.
Korean J Physiol Pharmacol 2024;28:303-312 https://doi.org/10.4196/kjpp.2024.28.4.303
© Korean J Physiol Pharmacol